New drug combo aims to free hepatitis b patients from daily pills
NCT ID NCT07135349
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether a new injection called BW-20507, combined with pegylated interferon alfa, can help people with chronic hepatitis B stop their daily antiviral medication (NUCs). About 209 adults with hepatitis B will receive the combination for 48 weeks. The main goal is to see how many can safely stop NUCs by week 72.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BW-20507 injection combined with pegylated interferon alfa
What this could lead to
If successful, this combination could help some patients with chronic hepatitis B stop taking daily antiviral pills (NUCs) while keeping the virus under control.
What could go wrong
This is an early-phase (Phase 2) trial with only 209 participants, so results may not apply to all patients. The treatment involves injections over 48 weeks and may cause side effects like flu-like symptoms from interferon.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Argo Investigative Site
Hefei, Anhui, 230022, China
-
Argo Investigative Site
Beijing, Beijing Municipality, 100015, China
-
Argo Investigative Site
Sichuan, Chengdu, China
-
Argo Investigative Site
Chongqing, Chongqing Municipality, 400000, China
-
Argo Investigative Site
Chongqing, Chongqing Municipality, China
-
Argo Investigative Site
Fuzhou, Fujian, 350000, China
-
Argo Investigative Site
Guangzhou, Guangdong, 510515, China
-
Argo Investigative Site
Shenzhen, Guangdong, 518000, China
-
Argo Investigative Site
Zunyi, Guizhou, 563000, China
-
Argo Investigative Site
Changzhou, Jiangsu, 213000, China
-
Argo Investigative Site
Xuzhou, Jiangsu, 22100, China
-
Argo Investigative Site
Nanchang, Jiangxi, 330000, China
-
Argo Investigative Site
Jiangxi, Nanchang, China
-
Argo Investigative Site
Shanghai, Shanghai Municipality, 2000001, China
-
Argo Investigative Site
Chengdu, Sichaun, 610041, China
-
Argo Investigative Site
Chengdu, Sichuan, 610041, China
-
Argo Investigative Site
Zhejiang, Wenzhou, China
-
Argo Investigative Site
Hangzhou, Zhejiang, 310000, China